2026年10月16日星期五
M
寰宇通鑑
グローバル速報
[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet

IL-6R blockade with tocilizumab disrupts pericyte– and tumor cell–driven IL-6/STAT3 signaling, enhancing docetaxel efficacy in ER+ breast cancer

出典 Nature 生命科学11 時間前
内容の要約

IL-6R blockade with tocilizumab disrupts pericyte– and tumor cell–driven IL-6/STAT3 signaling, enhancing docetaxel efficacy in ER+ breast cancer

当サイトはタイトルと要約のインデックスのみを提供しています。完全なコンテンツと著作権はすべて元の配信元に帰属します。原文リンクをクリックしてご覧ください。

原文へ
所属チャンネル
科学
所属地域
グローバル視点
原文の言語
English
項目番号
science-3aa545af

Comments 0 comments

No comments yet. Be the first.

IL-6R blockade with tocilizumab disrupts pericyte– and tumor cell–driven IL-6/STAT3 signaling, enhancing docetaxel efficacy in ER+ breast cancer · 寰宇通鑑